TOP TEN perturbations for Q9NZW4 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9NZW4
Selected probe(set): 221681_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9NZW4 (221681_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):2.396305
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

B-CLL study 6 / normal CD4+ T-cell sample

Relative Expression (log2-ratio):-1.6053495
Number of Samples:7 / 16
Experimental B-CLL study 6
Purified peripheral blood CD4+ T-cell samples obtained from patients with chronic lymphocytic B-cell leukemia (B-CLL). CD4+ T-cell samples were enriched from peripheral blood and stimulated on CD3-coated plates with 3g/ml anti-CD28 AIM-V serum-free medium for 40 hours.
Control normal CD4+ T-cell sample
Purified peripheral blood CD4+ T-cell samples obtained from healthy individuals. CD4+ T-cell samples were enriched from peripheral blood and stimulated on CD3-coated plates with 3g/ml anti-CD28 AIM-V serum-free medium for 40 hours.

polycystic ovary syndrome study 5 (16 wk pioglitazone) / polycystic ovary syndrome study 5 (before treatment)

Relative Expression (log2-ratio):-1.5830727
Number of Samples:9 / 10
Experimental polycystic ovary syndrome study 5 (16 wk pioglitazone)
Vastus lateralis muscle tissue obtained from insulin resistant subjects with polycystic ovary syndrome which were treated 16 weeks with antidiabetic agent pioglitazone (30mg/day). Samples were taken by needle biopsy under local anesthesia after 2 hours basal tracer equilibration for euglycemic-hyperinsulinemic clamp preceded by an over-night fast. The subjects manifested strong insulin resistance, oligoovulation, elevated free testosterone levels (>0.035nmol/l) and/or hirsutism (total Ferriman-Gallwey score >7), but no diabetes, hypertension, hyperprolactinemia, hypothyroidism and no adrenal enzyme defects. Further clinical characteristics at the end of the treatment period (mean ± SD): age (30.3 ± 2.1 years), BMI (33.0 ± 1.1), plasma glucose (5.6 ± 0.1 mmol/l), serum insulin (69 ± 12 pmol/l), plasma triglycerides (1.15 ± 0.16 mmol/l), glucose oxidation clamp (101 ± 12 mg/min^1 m^2), lipid oxidation clamp (16 ± 5 mg/min^1 m^2), non-oxidative glucose disposal during clamp (NOGD, 87 ± 14 mg/min^1 m^2).
Control polycystic ovary syndrome study 5 (before treatment)
Vastus lateralis muscle tissue obtained by needle biopsy under local anesthesia from insulin resistant subjects with polycystic ovary syndrome after 2 hours basal tracer equilibration for euglycemic-hyperinsulinemic clamp preceded by an over-night fast. The subjects manifested strong insulin resistance, oligoovulation, elevated free testosterone levels (>0.035nmol/l) and/or hirsutism (total Ferriman-Gallwey score >7), but no diabetes, hypertension, hyperprolactinemia, hypothyroidism and no adrenal enzyme defects. Further clinical characteristics (mean ± SD): age (30.3 ± 2.1 years), BMI (33.2 ± 0.9), plasma glucose (5.9 ± 0.2 mmol/l), serum insulin (125 ± 23 pmol/l), plasma triglycerides (1.43 ± 0.22 mmol/l), glucose oxidation clamp (80 ± 10 mg/min^1 m^2), lipid oxidation clamp (24 ± 4 mg/min^1 m^2), non-oxidative glucose disposal during clamp (NOGD, 58 ± 12 mg/min^1 m^2).

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):1.5320463
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):1.5249081
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

normal skeletal muscle tissue (pre-training; active) / normal skeletal muscle tissue (pre-training; sedentary)

Relative Expression (log2-ratio):-1.5126562
Number of Samples:17 / 24
Experimental normal skeletal muscle tissue (pre-training; active)
Vastus lateralis muscle tissue biopsy samples from 17 young healthy active Caucasian men. Resting skeletal muscle biopsies were taken before the endurance training program. Average parameters of patients were: age=29±6 y, height=1.82±0.5 m, body mass=81.8±9 kg, VO2max=4.1±0.5 L.min-1.
Control normal skeletal muscle tissue (pre-training; sedentary)
Vastus lateralis muscle tissue biopsy samples from 24 young sedentary healthy Caucasian men. Resting skeletal muscle biopsies were taken before the endurance training program. Average parameters of patients were: age=23±1 y, height=1.82±0.02 m, body mass=78.6±2.7 kg, VO2max=3.71±0.55 L.min-1.

stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)

Relative Expression (log2-ratio):1.4401093
Number of Samples:2 / 2
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):1.4209366
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

follicular lymphoma study 4 / normal CD4+ T-cell sample

Relative Expression (log2-ratio):-1.1932383
Number of Samples:8 / 16
Experimental follicular lymphoma study 4
Purified peripheral blood CD4+ T-cell samples obtained from patients with follicular lymphoma (FL; malignant lymphoma, nodular). CD4+ T-cell samples were enriched from peripheral blood and stimulated on CD3-coated plates with 3g/ml anti-CD28 AIM-V serum-free medium for 40 hours.
Control normal CD4+ T-cell sample
Purified peripheral blood CD4+ T-cell samples obtained from healthy individuals. CD4+ T-cell samples were enriched from peripheral blood and stimulated on CD3-coated plates with 3g/ml anti-CD28 AIM-V serum-free medium for 40 hours.

ulcerative colitis study 31 (active) / ulcerative colitis study 31 (quiescent)

Relative Expression (log2-ratio):-1.096756
Number of Samples:14 / 8
Experimental ulcerative colitis study 31 (active)
Colon biopsies of regions with involved mucosa from ulcerative colitis (UC) patients with active disease. Clinical and histological disease was assessed using the total Mayo score and the Matts score. None of the biopsies showed evidence of colitis-associated dysplasia or neoplasia.
Control ulcerative colitis study 31 (quiescent)
Colon biopsies of regions with involved mucosa from ulcerative colitis (UC) patients in remission. Clinical and histological disease was assessed using the total Mayo score and the Matts score. Patients had been in remission for at least 5 months before and after biopsy collection. None of the biopsies showed evidence of colitis-associated dysplasia or neoplasia.